Tanabe Pharma reports positive Phase 3 INSPIRE data for oral dersimelagon in EPP and XLP, showing improved light tolerance, reduced pain events, and a favorable safety profile.
Written By: Chikkula Pavan LKumar, PharmD
Reviewed By: Pharmacally Editorial Team
Tanabe Pharma has reported positive Phase 3 results from the INSPIRE study evaluating dersimelagon, an investigational oral therapy, in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The results were presented as a late-breaking oral session at the 2026 American Academy of Dermatology Annual Meeting on March 28, 2026.
The study met its primary endpoint and demonstrated clinically meaningful improvements across multiple secondary measures, positioning dersimelagon as a potential first-in-class oral treatment for these rare phototoxic disorders.
Dersimelagon is a novel, orally administered, non-peptide small molecule that selectively activates the melanocortin 1 receptor (MC1R). By targeting this pathway, it is designed to increase pain-free light exposure in patients with EPP and XLP. Tanabe Pharma is currently developing dersimelagon as a potential treatment for these conditions.
In the Phase 3 INSPIRE trial (NCT06144840), the drug significantly prolonged the time patients could tolerate sunlight before experiencing initial symptoms. The placebo-adjusted increase in average daily sunlight exposure time was 23.19 minutes during Weeks 12–16 (p=0.004), which further improved to 29.64 minutes at Week 16 in supplementary analysis.
The trial also met key secondary endpoints. Patients treated with dersimelagon reported significant improvements in Patient Global Impression of Change (PGIC) scores and experienced a 39% reduction in total pain events compared to placebo (p=0.004). These findings reinforce the clinical relevance of improved light tolerance in a condition where even brief exposure can trigger severe pain.
In terms of safety, dersimelagon was generally well tolerated. The most common adverse events included melanocytic nevi, headache, nausea, diarrhea, and skin hyperpigmentation, consistent with its MC1R-driven mechanism. No unexpected safety signals were reported.
The INSPIRE study enrolled 165 patients aged 12 to 75 years and was conducted as a global, randomized, double-blind, placebo-controlled trial with a 16-week treatment phase followed by an ongoing open-label extension. To date, dersimelagon has been studied in over 400 participants with EPP or XLP.
Akihisa Harada, Chief Executive Officer of Tanabe Pharma Corporation highlighted the significance of these results, noting that dersimelagon is the first oral therapy to demonstrate Phase 3 clinical benefit in both EPP and XLP. With Fast Track and Orphan Drug designations already granted in the U.S., Tanabe Pharma is now preparing for a rolling New Drug Application (NDA) submission.
EPP and XLP are rare genetic disorders of the heme biosynthesis pathway characterized by rapid onset of severe phototoxic pain following light exposure. Symptoms often begin in childhood and significantly limit daily activities. Current treatment options remain limited, particularly for adolescents, highlighting the unmet need addressed by this therapy.
Reference
Tanabe Pharma Announces Positive Data from Phase 3 INSPIRE Study of Dersimelagon in EPP and XLP, 30 March 2026, March 30, 2026 Tanabe Pharma Announces Positive Data from Phase 3 INSPIRE Study of Dersimelagon in EPP and XLP
INcreased Sun Exposure Without Pain in Research Participants with EPP or XLP (INSPIRE), ClinicalTrials.gov ID NCT06144840, https://clinicaltrials.gov/study/NCT06144840
About the Writer
Chikkula Pavan Kumar, Pharm.D. is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.